Rajeev Vibhakar
Concepts (383)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medulloblastoma | 36 | 2023 | 177 | 10.280 |
Why?
| Cerebellar Neoplasms | 26 | 2023 | 135 | 8.050 |
Why?
| Glioma | 14 | 2024 | 306 | 3.460 |
Why?
| Rhabdoid Tumor | 9 | 2022 | 80 | 3.070 |
Why?
| Brain Neoplasms | 20 | 2024 | 1022 | 2.860 |
Why?
| Gene Expression Regulation, Neoplastic | 22 | 2022 | 1167 | 2.770 |
Why?
| Radiation Tolerance | 7 | 2022 | 98 | 2.680 |
Why?
| Cell Cycle Proteins | 8 | 2022 | 565 | 2.460 |
Why?
| Cell Proliferation | 24 | 2023 | 2275 | 1.840 |
Why?
| Teratoma | 5 | 2022 | 92 | 1.740 |
Why?
| Cell Line, Tumor | 29 | 2023 | 2851 | 1.640 |
Why?
| Protein-Tyrosine Kinases | 4 | 2020 | 407 | 1.500 |
Why?
| Pyrazoles | 7 | 2022 | 363 | 1.310 |
Why?
| Proto-Oncogene Proteins c-myc | 4 | 2021 | 115 | 1.310 |
Why?
| Nuclear Proteins | 9 | 2023 | 597 | 1.300 |
Why?
| Ependymoma | 9 | 2020 | 169 | 1.220 |
Why?
| Proto-Oncogene Proteins | 4 | 2022 | 618 | 1.210 |
Why?
| Biomarkers, Tumor | 9 | 2021 | 1059 | 1.160 |
Why?
| Apoptosis | 18 | 2022 | 2484 | 1.150 |
Why?
| Pyrimidines | 8 | 2019 | 382 | 1.080 |
Why?
| Molecular Targeted Therapy | 4 | 2021 | 356 | 1.060 |
Why?
| Cyclin-Dependent Kinase 6 | 4 | 2020 | 37 | 1.050 |
Why?
| Brain Stem Neoplasms | 4 | 2021 | 90 | 1.030 |
Why?
| Antineoplastic Agents | 10 | 2022 | 1974 | 1.010 |
Why?
| Radiation-Sensitizing Agents | 2 | 2016 | 38 | 0.980 |
Why?
| Cell Transformation, Neoplastic | 2 | 2019 | 317 | 0.940 |
Why?
| Genes, myc | 3 | 2020 | 46 | 0.910 |
Why?
| Cellular Senescence | 3 | 2019 | 151 | 0.890 |
Why?
| Pyrimidinones | 4 | 2020 | 86 | 0.890 |
Why?
| MicroRNAs | 5 | 2020 | 637 | 0.890 |
Why?
| Hedgehog Proteins | 7 | 2022 | 175 | 0.880 |
Why?
| Cell Cycle | 11 | 2017 | 550 | 0.820 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 65 | 0.820 |
Why?
| Receptor, trkC | 1 | 2021 | 10 | 0.800 |
Why?
| Receptor, trkB | 1 | 2021 | 28 | 0.790 |
Why?
| Anilides | 3 | 2019 | 69 | 0.780 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 59 | 0.760 |
Why?
| Central Nervous System Neoplasms | 4 | 2019 | 128 | 0.750 |
Why?
| Gene Expression Profiling | 15 | 2024 | 1597 | 0.740 |
Why?
| Neoplastic Stem Cells | 3 | 2019 | 336 | 0.740 |
Why?
| SMARCB1 Protein | 2 | 2020 | 17 | 0.730 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 33 | 0.730 |
Why?
| DNA Repair | 1 | 2021 | 198 | 0.700 |
Why?
| Deoxycytidine | 1 | 2020 | 136 | 0.690 |
Why?
| Pteridines | 2 | 2016 | 16 | 0.680 |
Why?
| Cerebellum | 5 | 2022 | 203 | 0.660 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 446 | 0.660 |
Why?
| Glioblastoma | 3 | 2023 | 262 | 0.650 |
Why?
| Oligonucleotide Array Sequence Analysis | 10 | 2016 | 770 | 0.640 |
Why?
| Humans | 81 | 2024 | 118974 | 0.640 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 455 | 0.630 |
Why?
| Transcription Factors | 6 | 2023 | 1570 | 0.630 |
Why?
| Histones | 4 | 2020 | 552 | 0.630 |
Why?
| RNA, Small Interfering | 4 | 2022 | 564 | 0.580 |
Why?
| Vinblastine | 1 | 2016 | 68 | 0.580 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.580 |
Why?
| Blotting, Western | 8 | 2019 | 1194 | 0.570 |
Why?
| Vincristine | 1 | 2016 | 99 | 0.570 |
Why?
| Bilirubin | 1 | 2016 | 95 | 0.570 |
Why?
| Radiation, Ionizing | 3 | 2022 | 74 | 0.570 |
Why?
| Cell Survival | 8 | 2019 | 1047 | 0.550 |
Why?
| Tumor Cells, Cultured | 7 | 2020 | 874 | 0.530 |
Why?
| Mutation | 7 | 2022 | 3457 | 0.530 |
Why?
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 136 | 0.520 |
Why?
| Enzyme Inhibitors | 6 | 2020 | 827 | 0.520 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2012 | 60 | 0.520 |
Why?
| Transcriptome | 5 | 2022 | 756 | 0.510 |
Why?
| Child | 29 | 2024 | 19129 | 0.500 |
Why?
| Histone Deacetylase Inhibitors | 3 | 2023 | 200 | 0.480 |
Why?
| RNA, Messenger | 7 | 2014 | 2657 | 0.480 |
Why?
| Repressor Proteins | 3 | 2022 | 377 | 0.430 |
Why?
| Child, Preschool | 18 | 2021 | 9491 | 0.410 |
Why?
| Piperazines | 3 | 2022 | 316 | 0.400 |
Why?
| Mice | 14 | 2023 | 15520 | 0.400 |
Why?
| Epigenesis, Genetic | 4 | 2021 | 539 | 0.390 |
Why?
| Prognosis | 9 | 2020 | 3443 | 0.390 |
Why?
| Azepines | 3 | 2019 | 74 | 0.390 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 982 | 0.370 |
Why?
| Intracellular Space | 1 | 2010 | 69 | 0.370 |
Why?
| Neoplasms, Neuroepithelial | 2 | 2020 | 18 | 0.370 |
Why?
| Genes, Tumor Suppressor | 2 | 2007 | 77 | 0.360 |
Why?
| Chromatin | 4 | 2020 | 441 | 0.360 |
Why?
| Cisplatin | 3 | 2016 | 271 | 0.360 |
Why?
| Neoplasm Proteins | 2 | 2012 | 401 | 0.360 |
Why?
| Reactive Oxygen Species | 2 | 2022 | 576 | 0.350 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1390 | 0.350 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2020 | 740 | 0.350 |
Why?
| Real-Time Polymerase Chain Reaction | 4 | 2014 | 333 | 0.330 |
Why?
| Cell Differentiation | 6 | 2022 | 1753 | 0.330 |
Why?
| Drug Screening Assays, Antitumor | 4 | 2021 | 189 | 0.330 |
Why?
| Protein Kinase Inhibitors | 2 | 2014 | 811 | 0.330 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2019 | 74 | 0.330 |
Why?
| Infratentorial Neoplasms | 2 | 2019 | 50 | 0.320 |
Why?
| Animals | 15 | 2023 | 33381 | 0.320 |
Why?
| Quinazolines | 2 | 2022 | 245 | 0.310 |
Why?
| NF-kappa B | 4 | 2023 | 670 | 0.310 |
Why?
| DNA-Binding Proteins | 3 | 2017 | 1346 | 0.300 |
Why?
| B7 Antigens | 2 | 2020 | 11 | 0.300 |
Why?
| Aurora Kinases | 3 | 2012 | 28 | 0.300 |
Why?
| Single-Cell Analysis | 4 | 2022 | 187 | 0.300 |
Why?
| Mice, Nude | 3 | 2020 | 663 | 0.300 |
Why?
| Signal Transduction | 9 | 2021 | 4709 | 0.290 |
Why?
| Aurora Kinase A | 3 | 2012 | 52 | 0.290 |
Why?
| Combined Modality Therapy | 6 | 2019 | 1166 | 0.290 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2019 | 202 | 0.280 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 38 | 0.280 |
Why?
| Neoplasm Recurrence, Local | 4 | 2022 | 900 | 0.280 |
Why?
| Polycomb Repressive Complex 1 | 2 | 2020 | 51 | 0.270 |
Why?
| Triazoles | 2 | 2019 | 134 | 0.270 |
Why?
| Epigenomics | 3 | 2020 | 107 | 0.270 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 369 | 0.260 |
Why?
| Bone Morphogenetic Proteins | 2 | 2019 | 137 | 0.260 |
Why?
| Cord Blood Stem Cell Transplantation | 1 | 2005 | 96 | 0.250 |
Why?
| Autophagy | 2 | 2019 | 315 | 0.250 |
Why?
| Survival Rate | 5 | 2020 | 1720 | 0.240 |
Why?
| Abnormalities, Multiple | 1 | 2005 | 181 | 0.240 |
Why?
| Drug Resistance, Neoplasm | 2 | 2019 | 671 | 0.240 |
Why?
| Female | 23 | 2021 | 61565 | 0.230 |
Why?
| Metencephalon | 1 | 2022 | 1 | 0.220 |
Why?
| Cell Lineage | 2 | 2022 | 318 | 0.220 |
Why?
| Disease-Free Survival | 3 | 2016 | 649 | 0.220 |
Why?
| von Willebrand Diseases | 1 | 2022 | 13 | 0.210 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 40 | 0.210 |
Why?
| Spheroids, Cellular | 2 | 2012 | 56 | 0.210 |
Why?
| von Willebrand Factor | 1 | 2022 | 58 | 0.210 |
Why?
| Genome, Human | 3 | 2014 | 387 | 0.210 |
Why?
| DNA Copy Number Variations | 4 | 2021 | 167 | 0.210 |
Why?
| Tumor Microenvironment | 2 | 2022 | 454 | 0.210 |
Why?
| Radiation | 1 | 2021 | 26 | 0.200 |
Why?
| Pyridines | 3 | 2019 | 440 | 0.200 |
Why?
| Neural Stem Cells | 2 | 2012 | 120 | 0.200 |
Why?
| Mice, Transgenic | 3 | 2021 | 2025 | 0.190 |
Why?
| RNA, Long Noncoding | 2 | 2021 | 161 | 0.190 |
Why?
| Fatal Outcome | 1 | 2021 | 287 | 0.190 |
Why?
| Receptor, EphB4 | 1 | 2020 | 29 | 0.180 |
Why?
| Colony-Forming Units Assay | 2 | 2012 | 93 | 0.180 |
Why?
| Ephrin-B2 | 1 | 2020 | 42 | 0.180 |
Why?
| Antigens, Surface | 2 | 1997 | 156 | 0.180 |
Why?
| Craniospinal Irradiation | 1 | 2019 | 4 | 0.180 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 62 | 0.180 |
Why?
| Receptors, Nerve Growth Factor | 1 | 2019 | 15 | 0.180 |
Why?
| RNA, Small Nuclear | 1 | 2019 | 32 | 0.180 |
Why?
| Oncogene Proteins, Fusion | 2 | 2019 | 181 | 0.180 |
Why?
| Karyopherins | 1 | 2019 | 17 | 0.180 |
Why?
| Benzamides | 3 | 2019 | 176 | 0.180 |
Why?
| Dose-Response Relationship, Drug | 3 | 2017 | 1945 | 0.180 |
Why?
| Kaplan-Meier Estimate | 3 | 2017 | 842 | 0.180 |
Why?
| Adolescent | 12 | 2021 | 18480 | 0.170 |
Why?
| Male | 20 | 2021 | 57801 | 0.170 |
Why?
| Infant | 12 | 2021 | 8293 | 0.170 |
Why?
| Proteins | 3 | 2021 | 938 | 0.170 |
Why?
| Phenotype | 3 | 2024 | 3003 | 0.170 |
Why?
| Cell Self Renewal | 1 | 2019 | 51 | 0.170 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2021 | 814 | 0.160 |
Why?
| Chemoradiotherapy | 1 | 2019 | 200 | 0.160 |
Why?
| Base Sequence | 4 | 2012 | 2159 | 0.160 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 195 | 0.160 |
Why?
| Sulfonamides | 2 | 2022 | 445 | 0.160 |
Why?
| DNA Methylation | 4 | 2021 | 503 | 0.160 |
Why?
| Everolimus | 1 | 2017 | 64 | 0.150 |
Why?
| Cohort Studies | 6 | 2021 | 5116 | 0.150 |
Why?
| Recombinational DNA Repair | 1 | 2017 | 10 | 0.150 |
Why?
| Genes, p16 | 1 | 2017 | 18 | 0.150 |
Why?
| E2F Transcription Factors | 1 | 2017 | 55 | 0.150 |
Why?
| DNA Damage | 2 | 2017 | 357 | 0.150 |
Why?
| Morpholines | 1 | 2017 | 106 | 0.150 |
Why?
| Phthalazines | 1 | 2017 | 47 | 0.150 |
Why?
| Chromosome Aberrations | 1 | 2017 | 136 | 0.150 |
Why?
| Benzodiazepinones | 1 | 2016 | 14 | 0.150 |
Why?
| Cell Division | 2 | 2010 | 776 | 0.150 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 23 | 0.150 |
Why?
| Immunophenotyping | 1 | 2017 | 278 | 0.140 |
Why?
| Chloroquine | 1 | 2017 | 64 | 0.140 |
Why?
| Stem Cells | 1 | 2021 | 559 | 0.140 |
Why?
| Neoplasm Invasiveness | 2 | 2020 | 462 | 0.140 |
Why?
| Up-Regulation | 2 | 2016 | 872 | 0.140 |
Why?
| Microarray Analysis | 2 | 2017 | 124 | 0.140 |
Why?
| Electric Stimulation Therapy | 1 | 2017 | 74 | 0.140 |
Why?
| Urea | 1 | 2016 | 77 | 0.140 |
Why?
| Lysine | 2 | 2020 | 248 | 0.140 |
Why?
| Thiophenes | 1 | 2016 | 106 | 0.140 |
Why?
| Cancer Survivors | 1 | 2019 | 201 | 0.140 |
Why?
| Mitosis | 1 | 2016 | 172 | 0.130 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 420 | 0.130 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 180 | 0.130 |
Why?
| Tumor Suppressor Proteins | 1 | 2017 | 289 | 0.130 |
Why?
| Survival Analysis | 2 | 2010 | 1267 | 0.130 |
Why?
| Genomics | 3 | 2017 | 706 | 0.130 |
Why?
| HeLa Cells | 1 | 2016 | 583 | 0.130 |
Why?
| Promoter Regions, Genetic | 3 | 2017 | 1158 | 0.130 |
Why?
| Indoles | 1 | 2017 | 316 | 0.120 |
Why?
| Lymphocyte Activation | 2 | 2002 | 1067 | 0.120 |
Why?
| Brain | 2 | 2020 | 2490 | 0.120 |
Why?
| Flow Cytometry | 2 | 2019 | 1085 | 0.120 |
Why?
| STAT3 Transcription Factor | 1 | 2015 | 189 | 0.120 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 755 | 0.120 |
Why?
| Precision Medicine | 1 | 2017 | 363 | 0.120 |
Why?
| Cell Movement | 2 | 2020 | 896 | 0.110 |
Why?
| Phosphorylation | 4 | 2020 | 1633 | 0.110 |
Why?
| Cathepsin B | 1 | 2012 | 14 | 0.110 |
Why?
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.110 |
Why?
| Argonaute Proteins | 1 | 2012 | 28 | 0.110 |
Why?
| Wnt Proteins | 1 | 2014 | 140 | 0.110 |
Why?
| Genomic Structural Variation | 1 | 2012 | 7 | 0.110 |
Why?
| Quality of Life | 2 | 2023 | 2366 | 0.110 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2012 | 129 | 0.110 |
Why?
| Acetylcysteine | 1 | 2013 | 148 | 0.110 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 195 | 0.110 |
Why?
| Luciferases | 1 | 2012 | 143 | 0.110 |
Why?
| Retrospective Studies | 5 | 2019 | 12978 | 0.110 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 142 | 0.110 |
Why?
| Colorado | 1 | 2022 | 4196 | 0.100 |
Why?
| Tubulin | 1 | 2012 | 122 | 0.100 |
Why?
| Gene Expression Regulation | 1 | 2021 | 2445 | 0.100 |
Why?
| Carrier Proteins | 2 | 2012 | 726 | 0.100 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2012 | 99 | 0.100 |
Why?
| Telomerase | 1 | 2013 | 207 | 0.100 |
Why?
| Interleukin-6 | 1 | 2015 | 688 | 0.100 |
Why?
| Acetylation | 1 | 2011 | 217 | 0.100 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2017 | 532 | 0.100 |
Why?
| RNA Interference | 1 | 2012 | 460 | 0.100 |
Why?
| Adenosine | 1 | 2012 | 211 | 0.100 |
Why?
| Acetaminophen | 1 | 2013 | 244 | 0.090 |
Why?
| Radiosurgery | 1 | 2014 | 318 | 0.090 |
Why?
| Aging | 1 | 2020 | 1670 | 0.090 |
Why?
| Disease Models, Animal | 1 | 2019 | 3730 | 0.090 |
Why?
| Tyrosine | 2 | 2023 | 233 | 0.090 |
Why?
| Hydroxamic Acids | 2 | 2007 | 80 | 0.090 |
Why?
| Ki-67 Antigen | 2 | 2022 | 108 | 0.090 |
Why?
| Neoplasm Grading | 2 | 2021 | 258 | 0.090 |
Why?
| Superoxides | 1 | 2010 | 221 | 0.090 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2012 | 453 | 0.090 |
Why?
| Gene Silencing | 2 | 2007 | 177 | 0.090 |
Why?
| T-Lymphocytes | 1 | 1997 | 1774 | 0.090 |
Why?
| Kidney Neoplasms | 1 | 2013 | 334 | 0.080 |
Why?
| Histone Demethylases | 2 | 2022 | 28 | 0.080 |
Why?
| Cluster Analysis | 3 | 2017 | 481 | 0.080 |
Why?
| Down-Regulation | 1 | 2010 | 627 | 0.080 |
Why?
| Syndrome | 2 | 2005 | 344 | 0.080 |
Why?
| Young Adult | 5 | 2021 | 10793 | 0.070 |
Why?
| Nerve Tissue Proteins | 2 | 2012 | 551 | 0.070 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2021 | 310 | 0.070 |
Why?
| Neoplasms | 1 | 2021 | 2179 | 0.070 |
Why?
| Scrotum | 1 | 2006 | 25 | 0.070 |
Why?
| Premedication | 1 | 2005 | 40 | 0.070 |
Why?
| Exocrine Pancreatic Insufficiency | 1 | 2005 | 17 | 0.070 |
Why?
| RNA | 1 | 2012 | 833 | 0.070 |
Why?
| Transplantation Chimera | 1 | 2005 | 51 | 0.070 |
Why?
| Neuroblastoma | 1 | 2006 | 135 | 0.070 |
Why?
| Drug Synergism | 2 | 2017 | 339 | 0.070 |
Why?
| Anemia, Aplastic | 1 | 2005 | 30 | 0.070 |
Why?
| Computer Simulation | 2 | 2021 | 922 | 0.070 |
Why?
| Testicular Neoplasms | 1 | 2006 | 95 | 0.070 |
Why?
| Neutropenia | 1 | 2005 | 133 | 0.060 |
Why?
| Molecular Sequence Data | 2 | 2008 | 2871 | 0.060 |
Why?
| Case-Control Studies | 1 | 2012 | 3171 | 0.060 |
Why?
| Transplantation Conditioning | 1 | 2005 | 156 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2275 | 0.060 |
Why?
| Graft vs Host Disease | 1 | 2005 | 216 | 0.060 |
Why?
| Graft Survival | 1 | 2005 | 504 | 0.060 |
Why?
| Core Binding Factor alpha Subunits | 1 | 2022 | 1 | 0.060 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2023 | 145 | 0.060 |
Why?
| Otx Transcription Factors | 1 | 2022 | 12 | 0.060 |
Why?
| Weibel-Palade Bodies | 1 | 2022 | 3 | 0.050 |
Why?
| Lymphoproliferative Disorders | 1 | 2002 | 46 | 0.050 |
Why?
| T-Box Domain Proteins | 1 | 2022 | 95 | 0.050 |
Why?
| fas Receptor | 1 | 2002 | 98 | 0.050 |
Why?
| Gene Ontology | 1 | 2021 | 55 | 0.050 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2022 | 95 | 0.050 |
Why?
| Antigens, CD | 3 | 2002 | 460 | 0.050 |
Why?
| Genetic Heterogeneity | 1 | 2021 | 56 | 0.050 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 226 | 0.050 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 404 | 0.050 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 165 | 0.050 |
Why?
| Phagocytosis | 1 | 2023 | 364 | 0.050 |
Why?
| Muscle Proteins | 1 | 2022 | 219 | 0.050 |
Why?
| Ifosfamide | 1 | 2020 | 31 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2019 | 4596 | 0.050 |
Why?
| Risk Factors | 3 | 2021 | 9000 | 0.050 |
Why?
| Transcription Factor HES-1 | 1 | 2019 | 4 | 0.050 |
Why?
| Smoothened Receptor | 1 | 2019 | 5 | 0.050 |
Why?
| Adult | 5 | 2021 | 31512 | 0.050 |
Why?
| MyoD Protein | 1 | 2019 | 28 | 0.050 |
Why?
| Cyclophosphamide | 1 | 2020 | 222 | 0.050 |
Why?
| Gain of Function Mutation | 1 | 2019 | 30 | 0.050 |
Why?
| RNA Splice Sites | 1 | 2019 | 35 | 0.040 |
Why?
| Astrocytoma | 1 | 2020 | 113 | 0.040 |
Why?
| Carcinogenesis | 1 | 2021 | 182 | 0.040 |
Why?
| Apoptosis Regulatory Proteins | 2 | 1997 | 190 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 239 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 333 | 0.040 |
Why?
| Aminopyridines | 1 | 2019 | 85 | 0.040 |
Why?
| Autoimmune Diseases | 1 | 2002 | 398 | 0.040 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 1997 | 197 | 0.040 |
Why?
| Consensus | 1 | 2021 | 534 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2002 | 632 | 0.040 |
Why?
| RNA Splicing | 1 | 2019 | 243 | 0.040 |
Why?
| Alternative Splicing | 1 | 2019 | 193 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 574 | 0.040 |
Why?
| Drug Approval | 1 | 2018 | 77 | 0.040 |
Why?
| Treatment Outcome | 3 | 2017 | 9342 | 0.040 |
Why?
| Receptors, HIV | 1 | 2017 | 23 | 0.040 |
Why?
| Mucin-1 | 1 | 2017 | 18 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2017 | 28 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 59 | 0.040 |
Why?
| Homeodomain Proteins | 1 | 2021 | 468 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 104 | 0.040 |
Why?
| Transfection | 1 | 2019 | 888 | 0.040 |
Why?
| Global Health | 1 | 2019 | 310 | 0.040 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 1997 | 155 | 0.040 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2017 | 87 | 0.040 |
Why?
| DNA, Complementary | 1 | 1997 | 268 | 0.040 |
Why?
| Jurkat Cells | 1 | 1997 | 134 | 0.040 |
Why?
| Microscopy, Confocal | 1 | 2017 | 314 | 0.030 |
Why?
| Radiotherapy | 1 | 2017 | 187 | 0.030 |
Why?
| Genetic Variation | 1 | 2021 | 926 | 0.030 |
Why?
| Macrophages | 1 | 2023 | 1324 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 348 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2017 | 356 | 0.030 |
Why?
| Canada | 1 | 2016 | 340 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 88 | 0.030 |
Why?
| Health Status | 1 | 2019 | 726 | 0.030 |
Why?
| Zinc Finger Protein Gli2 | 1 | 2014 | 3 | 0.030 |
Why?
| Cytogenetics | 1 | 2014 | 10 | 0.030 |
Why?
| Hematopoietic Stem Cells | 1 | 1997 | 359 | 0.030 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2014 | 17 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2014 | 52 | 0.030 |
Why?
| Middle Aged | 3 | 2021 | 27617 | 0.030 |
Why?
| Myeloid Cells | 1 | 2015 | 128 | 0.030 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2014 | 66 | 0.030 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2014 | 56 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 499 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 56 | 0.030 |
Why?
| Gene Expression | 2 | 2010 | 1489 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2016 | 3174 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 180 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2017 | 1691 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2013 | 381 | 0.030 |
Why?
| Gene Duplication | 1 | 2012 | 64 | 0.030 |
Why?
| B-Lymphocytes | 1 | 1997 | 770 | 0.030 |
Why?
| Methylation | 1 | 2012 | 204 | 0.030 |
Why?
| Monocytes | 1 | 2015 | 513 | 0.030 |
Why?
| Translocation, Genetic | 1 | 2012 | 92 | 0.030 |
Why?
| Inflammation | 1 | 2023 | 2566 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2015 | 502 | 0.030 |
Why?
| Glutathione | 1 | 2013 | 324 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 4908 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2014 | 1125 | 0.020 |
Why?
| Genome | 1 | 2012 | 277 | 0.020 |
Why?
| Age Factors | 1 | 2017 | 2995 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2012 | 462 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1868 | 0.020 |
Why?
| Disease Progression | 1 | 2016 | 2490 | 0.020 |
Why?
| Genotype | 1 | 2013 | 1882 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2019 | 4708 | 0.020 |
Why?
| Cytokines | 1 | 2015 | 1900 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2014 | 2874 | 0.020 |
Why?
| Azacitidine | 1 | 2006 | 119 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2012 | 2062 | 0.020 |
Why?
| Risk Assessment | 1 | 2014 | 3057 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2012 | 2436 | 0.010 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 83 | 0.010 |
Why?
| Lectins, C-Type | 1 | 2002 | 63 | 0.010 |
Why?
| Receptors, Interleukin-2 | 1 | 2002 | 65 | 0.010 |
Why?
| Cytoplasm | 1 | 2002 | 269 | 0.010 |
Why?
| Interleukin-4 | 1 | 2002 | 215 | 0.010 |
Why?
| Interleukin-2 | 1 | 2002 | 416 | 0.010 |
Why?
| Infant, Newborn | 1 | 2011 | 5255 | 0.010 |
Why?
| T-Lymphocyte Subsets | 1 | 2002 | 396 | 0.010 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2002 | 359 | 0.010 |
Why?
| Interferon-gamma | 1 | 2002 | 736 | 0.010 |
Why?
| Restriction Mapping | 1 | 1997 | 76 | 0.010 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 1997 | 28 | 0.010 |
Why?
| Interleukin-7 | 1 | 1997 | 44 | 0.010 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 1997 | 155 | 0.010 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1997 | 80 | 0.010 |
Why?
| Genes | 1 | 1997 | 231 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 1997 | 372 | 0.010 |
Why?
| Calcium | 1 | 2002 | 1169 | 0.010 |
Why?
| Bone Marrow | 1 | 1997 | 255 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 1997 | 1206 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1997 | 2071 | 0.010 |
Why?
| Cells, Cultured | 1 | 1997 | 4077 | 0.010 |
Why?
|
|
Vibhakar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|